Efficacy and safety of addition of empagliflozin in diabetic patients uncontrolled with glimepiride + metformin + teneligliptin
Abstract
BACKGROUND \nThe aim of this study was to evaluate the efficacy and safety of empagliflozin as an add-on drug in type 2 diabetes mellitus \n(T2DM) patients demonstrating inadequate disease control to triple drug treatment of glimepiride, metformin and teneligliptin. \nMATERIALS AND METHODS \nThe prospective, observational study, conducted in a clinical setting, included subjects with T2DM, aged between 40-70 years, \nwith inadequate disease control to triple drug treatment (glimepiride, metformin and teneligliptin) and glycated haemoglobin \n(HbA1c) of >7.5%. Clinical parameters such as serum creatinine, urea, HbA1c, fasting and postprandial blood sugar levels, and \nweight was measured before and after the study. The pre-and post- anthropometric and laboratory parameters were compared \nusing paired t-test and Wilcoxon signed-rank test. \nRESULTS \nThe study included 41 subjects with a mean age and disease duration of 58±5.13 years and 5±2.10 years respectively. Fasting \nand postprandial blood sugar levels, weight and HbA1c% of the subjects following treatment showed significant (P 0.7% reduction. Adverse reactions noted in the subjects included mild hypoglycaemia, urinary \ntract infection and mycotic infection. \nCONCLUSION \nEmpagliflozin can provide significant clinical benefits for T2DM patients, showing inadequate control to triple drug treatment of \nmetformin, glimepiride and teneligliptin
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.